Beur schreef op 17 september 2018 12:26:
[...]Nog maar weer een keertje dan uit het CV van Dr.Jan de Kerpel van Kempen, door de Financial Times 3x verkozen tot beste biotechanalist van Europa:
R&D Director at Devgen N.V.
Invented and led the discovery, development and registration of the novel products. Tasks included daily management of nematicide business, strategy, IP, budgeting, M&A evaluations, ...
Participate in business development by means of evaluating global expansion opportunities, distribution negotiations, supply chain management, due dilligence.
Director of R&D team and chemical operations staff (~15 FTE, mainly MSc & PhD level)
Project leader in human therapeutics business (focus on different cardiovascular and metabolic diseases);
Initiation and implementation of enhanced R&D outsourcing (Europe, Asia);
Medicinal chemistry section leader, acting director of medicinal chemistry
Achievements: successful registration of two novel products, which entered the US and Asian markets. Obtained government research grant of >€ 3m. Created and lead a new business entity. Work resulted in several granted patents on new drug development candidates, currently further developed in a spin-off pharma company (Amakem)
Senior Scientist at Tibotec
Drug discovery and preclinical R&D of new HIV drugs, resulting in currently marketed products by JNJ (Prezista and Intelence);
Named inventor on several patents of new drugs and screening technologies;
Project leader for several discovery related projects;
Instrumental in enhancing the capacity and capability of the discovery unit (screening-chemistry-biology-preclinical);
Miscellaneous: research liaison contact between Tibotec USA and Tibotec NV (HQ, Belgium) and worked for Tibotec USA (Washington DC)
Maar goed, ook de meest deskundige op het gebied van biotech kan mis zitten. Zoals ik zelf ook denk dat hij nu mis zit met zijn koersdoel van 0,60